AbbVie (ABBV) shares rallied in premarket trading after the company reported a strong first-quarter beat, exceeding analyst expectations for both earnings per share and revenue. First-quarter adjusted EPS came in at $2.65 per share against a consensus of $2.59, while total revenue reached $15 billion,...
Cantor Fitzgerald has raised its price target for AbbVie (NYSE: ABBV) from $265 to $285, maintaining an overweight rating. This follows a mixed landscape of recent analyst actions, including JPMorgan Chase increasing its target to $280 and DZ Bank upgrading the stock to a strong...
Arbor Capital Management Inc. ADV established a new position in AbbVie Inc. (NYSE: ABBV) during the first quarter, purchasing 27,001 shares valued at approximately $5.63 million. This acquisition makes AbbVie the firm's largest holding, accounting for roughly 4.6% of its portfolio. Concurrently, several other major...
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic...
AbbVie reported record financial results at its annual meeting held on May 9, citing total net revenues of $61.2 billion that exceeded initial expectations by over $2 billion. CEO Rob Michael highlighted an all-time high for revenue driven by an 8.6% sales growth, which more...
AbbVie (ABBV) recently reported Q1 2026 revenue of $15 billion, surpassing the consensus estimate of $14.72 billion by $280 million and representing a 12.43% year-over-year increase. While GAAP net income fell 45.96% due to significant investment charges of $744 million in intellectual property research and...
AbbVie reported its financial results for the fourth quarter and full year 2025, highlighting record net sales achieved in the second full year following the loss of U.S. exclusivity for its key drug, Humira. Robert A. Michael, Chairman and CEO, described 2025 as an outstanding...
AbbVie Inc. reported first-quarter 2026 results that significantly exceeded analyst expectations, with adjusted earnings per share (EPS) of $2.65 and total net revenues reaching $15.0 billion, representing a 12.4% increase year-over-year. CEO Rob Michael described the performance as exceeding expectations across the diverse portfolio, while...
AbbVie Inc. (NYSE: ABBV) shares rose 1.4% to $256.80 following a price target upgrade from Canaccord Genuity, which raised its target from $273.00 to $282.00 while maintaining a buy rating. The stock reached an intraday high of $258.38 with trading volume declining 38% from the...
Andra AP fonden significantly increased its stake in AbbVie Inc. (NYSE: ABBV) by 44.2% during the first quarter, acquiring an additional 86,969 shares to bring its total holding to 283,811 shares valued at $61.7 million. This investment makes AbbVie the fund's 18th largest position, representing...
Adams Diversified Equity Fund Inc. reduced its position in AbbVie Inc. by 31.1% in the first quarter, selling 58,300 shares to hold a remaining stake of 129,400 shares valued at $28.1 million. While this major fund decreased its exposure, several smaller institutional investors including Chelsea...
في 23 يونيو 2026، أعلنت شركة AbbVie (ABBV) عن موافقات تنظيمية هامة تشمل الموافقة الكندية على عقار Boey لتحسين خطوط الوجه لدى البالغين، وهو أول نوع مصلي E معتمد من التوكسين العصبي البوتولينوم لهذا الغرض. كما وافقت المفوضية الأوروبية على عقار Maviret لعلاج عدوى فيروس...
AbbVie (NYSE: ABBV) is described as an underrated growth story with CEO Robert A. Michael reporting that the company exceeded expectations in Q1 2026. Despite shares trading at $221.59, down 1.43% year-to-date, revenue accelerated by 12.4% year-over-year. Immunology revenue specifically hit $7.29 billion, driven by...
AbbVie (ABBV) shares gained approximately 5% following the release of robust first-quarter fiscal 2026 results on April 29, which beat analyst estimates for both earnings per share and sales. The company further strengthened investor confidence by raising its full-year guidance for 2026, updating earnings per...
AbbVie (NYSE: ABBV) is highlighted as a compelling investment opportunity ahead of its July 31 Q2 earnings report, driven by strong financial metrics and successful product transitions. The company trades at a forward P/E of 18x with a PEG ratio of 0.43 and a low...
AbbVie (NYSE: ABBV) stock received a price target boost from Canaccord Genuity, which raised its objective from $273.00 to $282.00 while maintaining a 'buy' rating, suggesting potential upside of 9.81% from current levels. This follows a series of positive analyst actions in July and early...
The article compares AbbVie (ABBV) and Baxter International (BAX), concluding that while both recently displayed a 'golden cross' technical signal, only AbbVie represents a viable option for income-focused retirement portfolios. AbbVie's signal is described as widening with rising moving averages, whereas Baxter's is characterized as...
Institutional investors have recently adjusted their positions in AbbVie Inc. (NYSE: ABBV), with AMG National Trust Bank increasing its stake by 20.2% to own 27,977 shares valued at $6.085 million in the first quarter. Other notable holders include Waycross Partners LLC, which owns 182,476 shares...
AbbVie Inc. (NYSE: ABBV) reported Q1 2023 revenue of $12.23 billion, a ~10% year-over-year decline, and adjusted EPS of $2.46, down 22%, primarily due to the anticipated impact of Humira's patent expiration. Despite this earnings contraction, the company maintained resilient performance with strong cash generation,...
Apella Capital LLC significantly increased its stake in AbbVie Inc. (NYSE: ABBV) by 97.9% in the first quarter, purchasing an additional 10,041 shares to hold a total of 20,298 shares valued at $4.23 million. Several other institutional investors, including Thoma Capital Management LLC and Consilium...
